article
Thriving biotech: three stocks building momentum
In this article, Dmytro Spilka explores three promising biotechs that have seen growth in the last year and why they may continue to garner interest.
List view / Grid view
Biogen
news
Big pharma establishes new industry standards group
Pharma companies involved include Allergan, AstraZeneca, Biogen, GlaxoSmithKline, Novartis, and Pfizer.
news
Biogen joins the Centre for Therapeutic Target Validation
8 February 2016 | By Victoria White
Biogen’s new membership follows the launch of the new CTTV Target Validation Platform, which helps researchers identify therapeutic targets for new medicines...
news
An interview with Uwe Gudat from Merck Serono, speaker at the 4th Annual Biosimilars & Biobetters Congress, 18-19 April 2016, London
13 January 2016 | By Oxford Global
In anticipation of our 4th Annual Biosimilars & Biobetters Congress, we spoke to one our expert speakers about the some of the key issues in the industry...
news
Launch of Dementia Discovery Fund to deliver new dementia treatments by 2025
21 October 2015 | By Kate Douetil
This innovative new global investment fund has gained support from a wide variety of investors, including the UK Government’s Department of Health (DoH), Alzheimer’s Research UK and world-leading major pharmaceutical companies Biogen, GlaxoSmithKline, Johnson & Johnson, Lilly, Pfizer and Takeda...
news
Biogen to work with Genomics to refine drug target selection
5 October 2015 | By Victoria White
Biogen will leverage findings from Genomics’ integrated database and analysis tools, which will be used to guide drug research and development...
news
Biogen sparks up strategic alliance with the Parkinson’s Institute and Clinical Centre
27 July 2015 | By Victoria White
Biogen and the Parkinson’s Institute have entered a strategic alliance focused on enhancing the understanding of the underlying biology of Parkinson’s...
news
Biogen and AGTC team up to develop gene therapies for ophthalmic diseases
2 July 2015 | By Victoria White
Biogen and AGTC have announced a broad collaboration and license agreement to develop gene therapies for multiple ophthalmic diseases...
article
Antibody Discovery Technologies: the partnership between academia and biopharma in the therapeutic monoclonal antibody success story
The use of monoclonal antibodies and antibody-based molecules as therapeutics to treat patients suffering with severe disease has become a major success story. Due to the exquisite specificity with which they interact with their antigen and the fact that their large binding surface can intervene at sites and targets not…
news
Probiodrug announces its intention to launch an Initial Public Offering and listing on Euronext Amsterdam
25 September 2014 | By Probiodrug
Probiodrug AG announces its intention to raise new funds through an Initial Public Offering and listing on Euronext Amsterdam...
news
Biogen Idec and AbbVie announce positive top-line results from Phase 3 study investigating daclizumab high-yield process in multiple sclerosis
16 June 2014 | By Biogen Idec
Biogen Idec and AbbVie announced positive top-line results from the Phase 3 DECIDE clinical trial, designed to evaluate the superiority of once-monthly, subcutaneous daclizumab high-yield process...
news
Quintiles and Biogen Idec announce comprehensive clinical development partnership
24 April 2014 | By Biogen Idec
Quintiles and Biogen Idec have entered into a five-year strategic clinical development agreement...
news
Eisai and Biogen Idec enter collaboration to develop and commercialize Alzheimer’s disease treatments
5 March 2014 | By Biogen Idec
Eisai Co., Ltd. and Biogen Idec announced that they have entered into a collaboration to develop and commercialize two of Eisai’s clinical candidates for Alzheimer’s disease, E2609 and BAN2401...